Impel Neuropharma Inc is a biotechnology business based in the US. Impel Neuropharma shares (IMPL) are listed on the NASDAQ and all prices are listed in US Dollars. Impel Neuropharma employs 129 staff and has a trailing 12-month revenue of around $5.2 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $5.67 |
|---|---|
| 52-week range | $5.64 - $14.28 |
| 50-day moving average | $7.65 |
| 200-day moving average | $7.69 |
| Wall St. target price | $36.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-4.57 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $5.67 from 2022-09-28
| 1 week (2022-09-23) | -1.90% |
|---|---|
| 1 month (2022-08-30) | -21.36% |
| 3 months (2022-06-30) | -39.16% |
| 6 months (2022-03-30) | -16.12% |
| 1 year (2021-09-30) | -53.45% |
|---|---|
| 2 years (2020-09-26) | N/A |
| 3 years (2019-09-26) | N/A |
| 5 years (2017-09-26) | N/A |
| Revenue TTM | $5.2 million |
|---|---|
| Gross profit TTM | $-23,000 |
| Return on assets TTM | -59.59% |
| Return on equity TTM | -369.28% |
| Profit margin | 0% |
| Book value | $0.17 |
| Market capitalisation | $135.1 million |
TTM: trailing 12 months
We're not expecting Impel Neuropharma to pay a dividend over the next 12 months.
Impel Pharmaceuticals Inc. , a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
We’ve rounded up stats on some of the most popular wheat stocks, along with information on how these stocks compare and how to invest.